Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .
Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study
Renal transplant recipients ( RTR ) have an increased risk of premature cardiovascular disease . The ALERT study is the first trial to evaluate the effect of statin therapy on cardiac outcomes following renal transplantation . Patients initially r and omized to fluvastatin or placebo in the 5–6 year ALERT study were offered open‐label fluvastatin XL 80 mg/day in a 2‐year extension to the original study . The primary endpoint was time to first major adverse cardiac event ( MACE ) . Of 1787 patients who completed ALERT , 1652 ( 92 % ) were followed in the extension . Mean total follow‐up was 6.7 years . Mean LDL‐cholesterol was 98 mg/dL ( 2.5 mmol/L ) at last follow‐up compared to a pre‐ study level of 159 mg/dL ( 4.1 mmol/L ) . Patients r and omized to fluvastatin had a reduced risk of MACE ( hazards ratio [ HR ] 0.79 , 95 % CI 0.63–0.99 , p = 0.036 ) , and a 29 % reduction in cardiac death or definite non‐fatal MI ( HR 0.71 , 95 % CI 0.55–0.93 , p = 0.014 ) . Total mortality and graft loss did not differ significantly between groups . Fluvastatin produces a safe and effective reduction in LDL‐cholesterol associated with reduced risk of MACE in RTR . The lipid‐lowering and cardiovascular benefits  of fluvastatin are comparable to those of statins in other patient groups , and support use of fluvastatin in RTR
Results : BP and lipid levels tended to come together soon in the post-trial period .
Conclusion : Benefits of BPL and lipid lowering on all-cause and cardiovascular mortality were persistent , but attenuated , after discontinuation of r and omized treatment , indicating the importance of continuing therapy
Objective : Persistent long-term benefits after discontinuation of treatment have been suggested for blood pressure-lowering and lipid-lowering treatment .
We conducted a systematic review to assess the long-term effects of  blood pressure ( BP ) lowering ( BPL ) and lipid lowering on all-cause and cardiovascular mortality after discontinuation of r and omized treatment .